MC 510051Alternative Names: MF-EA-371 alpha
Latest Information Update: 02 Oct 2000
At a glance
- Originator Daiichi Pharmaceutical; Essential Therapeutics [CEASED]
- Class Antibacterials
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Pseudomonal infections
Most Recent Events
- 02 Oct 2000 Discontinued-Preclinical for Pseudomonal infections in USA (Unknown route)